A new way to prepare cells for advanced treatments
Adaptable and scalable electroporation for cellular therapy
This project is creating a new, more efficient way to prepare cells for advanced treatments like CAR-T therapy, which helps patients with certain blood cancers.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cytequest, INC. NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-11163425 on NIH RePORTER |
What this research studies
Cellular therapies, such as CAR-T for blood cancers, use living cells as medicine to fight disease. Current CAR-T treatments often rely on viruses to modify cells, which can be slow and may have potential drawbacks. This project is developing a new method called electroporation to deliver genetic material into cells more safely and quickly. The goal is to create a flexible system that can be used for both early research and large-scale manufacturing of these cell therapies. This new platform aims to make cell therapy production more efficient and reliable for patients.
Who could benefit from this research
Good fit: Patients who might benefit from advanced cellular therapies, particularly those with hematological cancers currently treated with CAR-T therapy, are the ultimate focus of this technology.
Not a fit: Patients whose conditions are not treatable with cellular therapies or who do not require cell modification would not directly benefit from this specific technology development.
Why it matters
Potential benefit: If successful, this technology could make advanced cell therapies, such as CAR-T, more accessible, safer, and faster to produce for patients with serious diseases.
How similar studies have performed: Electroporation is a known method for cell modification, but this project focuses on developing a new, scalable platform specifically for advanced cell therapy manufacturing.
Where this research is happening
Ithaca, United States
- Cytequest, INC. — Ithaca, United States (Active)
Researchers
- Principal investigator: Craighead, Harold G — Cytequest, INC.
- Study coordinator: Craighead, Harold G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.